Compare FORR & MBOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FORR | MBOT |
|---|---|---|
| Founded | 1983 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 154.9M | 135.7M |
| IPO Year | 1996 | N/A |
| Metric | FORR | MBOT |
|---|---|---|
| Price | $6.30 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 95.2K | ★ 2.3M |
| Earning Date | 02-12-2026 | 03-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $403,871,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3,119.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.22 | $1.25 |
| 52 Week High | $15.26 | $4.67 |
| Indicator | FORR | MBOT |
|---|---|---|
| Relative Strength Index (RSI) | 23.12 | 55.65 |
| Support Level | $6.22 | $1.86 |
| Resistance Level | $7.40 | $2.16 |
| Average True Range (ATR) | 0.41 | 0.14 |
| MACD | -0.17 | 0.03 |
| Stochastic Oscillator | 2.05 | 73.15 |
Forrester Research Inc provides independent research, data, and advisory services. It operates through the following segments: The Research segment develops and delivers research, connect, and analytics products; The consulting segment includes the revenues and the related costs of the company's consulting organization, and the Events segment is engaged in developing and hosting in-person and virtual events.
Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.